Biotech News
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
ir.pmvpharma.com2026-05-06 15:03 EST
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Interim analysis from Phase 2 PYNNACLE trial expected mid-2025; PMV plans to provide interim analysis data for